Wells Fargo
RLMD icon

Wells Fargo’s Relmada Therapeutics RLMD Stock Holding History

Wells Fargo’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,800
Closed -$437K – 7684
2022
Q3 		$437K Sell
11,800
-8,200
-41% -$227K ﹤0.01% 3768
2022
Q2 		$380K Buy
+20,000
New +$436K ﹤0.01% 3901

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo's RLMD Position: Q2 2026 in Review

Wells Fargo opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 86,263 shares worth $597K. The stake represents ﹤0.01% of the portfolio and ranks #4496 among its holdings. This is a return to the name: Wells Fargo previously reported a position in RLMD as recently as Q4 2024.

Wells Fargo first reported a position in RLMD in Q4 2019 and has held it in 22 quarters since. The position peaked at $1.74M in Q2 2020. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Wells Fargo held 86,263 shares of Relmada Therapeutics worth $597K as of Q2 2026.
  • Relmada Therapeutics was a new Wells Fargo position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4496 holding.
  • Wells Fargo first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Wells Fargo's Relmada Therapeutics position peaked at $1.74M in Q2 2020.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.